With the end of 2022 in sight over the Thanksgiving holiday horizon, the US FDA drugs center brought its novel approvals count to 29 with the approvals of ImmunoGen, Inc.’s antibody-drug conjugate Elahere for a targeted ovarian cancer claim and Provention Bio, Inc.’s anti-CD3 antibody Tzield to delay onset of type 1 diabetes.
Both biologics face challenges to identifying patients for a new therapy setting